Lipoprotein(a) as a marker for coronary heart disease

British Journal of Clinical Practice

Volumn , Issue SUPPL. 77a, 1996, Pages 54-61

  Duriez, P ^a   Dallongeville, J ^a   Fruchart, J C ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; LIPOPROTEIN A;

BLOOD; CASE CONTROL STUDY; CHEMISTRY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; GENETICS; HUMAN; PROSPECTIVE STUDY; REVIEW; RISK FACTOR;

BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERIOSCLEROSIS; CORONARY DISEASE; HUMANS; LIPOPROTEIN(A); PROSPECTIVE STUDIES; RISK FACTORS;

EID: 0029693552     PISSN: 00070947     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (72)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Mitrobiol Stand 1963; 59: 369-382.
2. Berg K. Genetics of atherogenic Lp(a) lipoprotein. In: Berg K, Rollerstol N, Refsum S, Eds. From Phenotype to Gene in Common Disorders. Copenhagen: Munksgaard. 1990; 138-162.
3. Berg K. Lp(a) lipoprotein: an overview. In: Scanu AM, Ed. Lipoprotein(a). New York: Academic Press, 1990; 1-24.
4. Dahlen GH. Lipoprotein(a) in relation to atherosclerotic disease. Prog Clin Biol Res 1988; 255: 27-36.
5. Loscalzo J. Lipoprotein(a): a unique risk factor for atherothrombotic disease. Arteriosclerosis 1990; 10: 672-679.
6. Utermann G. Weber W. Protein composition of Lp(a) lipoprotein for human plasma. FEBS Lett 1983; 154: 357-361.
7. Gaubatz JW, Heideman G. Gotto AM et al. Human plasma lipoprotein(a): structural properties. J Biol Chem 1983; 258: 4582-4589.
8. Ealon DL, Fless GM, Kohn WJ et al. Partial amino acid sequence of apolipoprotein(a) shows that it is homologous to plasminogen. Proc Natl Acad Sci USA 1987; 84: 3224-3228.
9. McLean JW, Tomlinson JE, Kuang W et al. cDNA sequence of human apolipoprotein(a) is homologous to plasminogen. Nature 1987; 330: 132-137.
10. Frank SL. Klisak I, Sparkes RS et al. The apolipoprotein(a) gene resides on human chromosome 6q 26-27, in close proximity to the homologous gene for plasminogen. Hum Genet 1988; 79: 352-356.
11. Lindhal G. Gersdorf E, Menzel HJ et al. The gene for the Lp(a) specific glycoprotein is closely linked to the gene for plasminogen on chromosome 6. Hum Genet 1989; 81: 149-152.
12. Utermann GH. Menzel J. Kraft HG et al. Lp(a) glycoprotein phenolypes: inheritance and relation to Ep(a) lipoprotein concentrations in plasma. J Clin Invest 1987; 80: 458-465.
13. Boerwinkle E, Menzel HJ. Kraft HG et al. Genetics of the quantitative Lp(a) lipoprotein trait. III: contribution ol Lp(a) glycoprotein phenotypes to normal lipid variation. Hum Genet 1987; 82: 73-78.
14. Lackner C, Boerwinkle E, Leffert CC et al. Molecular basis of apolipoprotein(a) isoform size heterogeneity as revealed by pulsed field gel electrophoresis. J Clin Invest 1991 ; 87: 2153-2161.
15. Havekes L. Vermeer BJ. Brugman T et al. Binding of Lp(a) to the low density lipoprotein receptor of human fibroblasts. FEBS Lett 1981; 132: 169-173.
16. Maartmann-Moe K. Berg K. Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor. Clin Genet 1981; 20: 352-362.
17. Floren CH, Albers JJ. Bierman EL. Uptake of Lp(a) lipoprolein by cultured fibroblasts. Biochem Biophys Res Commun 1981; 102: 636-639.
18. Armstrong VW. Walli AK. Seidel D. Isolation, characterization, and uptake in human fibroblasts of an apo(a)-free lipoprotein obtained on reduction of lipoprotein(a). J Lipid Res 1985; 26: 1314-1323.
19. Krempler F. Kostner GM. Roscher A et al. Studies on the role of specific cell surface receptors in the removal of lipoprotein(a) in man. J Clin Invest 1983; 71: 1431-1441.
20. Mann AW. Kraft HG, Rader JJ et al. Human in vivo catabolism of lipoprotein(a). Circulation 1989; 80: 11-181.
21. Hofman SL. Eaton DL. Brown MS et al. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 1990; 85: 1542-1547,
22. Haberland ME. Fless G. Seanu AM el ul. Modification of Lp(a) by maiondiaidehyde leads to avid uptake by human monocyte-macrophages. Circulation 1989; 80: 11-163.
23. Lescalzo J, Weinfeld M, Fless GM et al. Lipoprotein(a) fibrin binding and plasminogen activation. Arteriosclerosis 1990; 10: 240-245.
24. Harpel PC, Gordon BA, Parker TS. Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogcn and fibrin. Proc Natl Acad Sci USA 1989; 86:3847-3851.
25. Edelberg JM, Gonzalez-Gronow M, Pizzo SV. Lipoprotein(a) inhibits streptokinase mediated activation of human plasminogen. Biochemistry 1989; 28: 2370-2374.
26. Karadi I, Kostner GM, Gries A et al. Lipoprotein(a) and plasminogen are immunochemically related. Biochim BiophysActa 1988; 960: 91-97.
27. Eftingin OR, Hajjar DP, Hajjar KA et al. Lipoprotein(a) regulation PAI 1 expression in endothelial cells. J Biol Chem 1991; 266: 2459-2465.
28. De Rijke YB. Jürgens G, Hesseis EMAJ et ai. In vivo fate and scavenger receptor recognition of oxidized lipoprotein(a) isoforms in rats. J Lipid Res 1992; 33: 1315-1326.
29. Haberland ME, Fless GM, Scanu AM et al. Maiondiaidehyde modification of lipoprotein (a) produces avid uptake by human monocytemacrophages. J Biol Chem 1992; 267: 4143-4151.
30. Naruszewiez M. Selinger E, Davignon J. Oxidative modification of Lp(a) and the effect of carotene. Metabolism 1992; 11: 1-9.
31. Jürgens G. Chen Q. Estervaucr H et al. Immunostaining of human autopsy aortas with antibodies to modified apolipoprotcin B and apolipoproiein(a). Arterioscler Thromb 1993; 13: 1689-1699.
32. Lawn RE. Wade DP, Hammer RE et al. Atherogenesis in transgenic mice expressing human lipoprotein(a). Nature 1992; 360: 670-671.
33. Dahlen G. Berg K. Gillnas T et al. Lp(a) lipoprotein/prebeta-1 lipoprotein in Swedish middle-aged males and in patients with coronary heart disease. Clin Genet 1975; 7: 334.
34. Durrington PN. lohola M. Hunt L et al. Apolipoprotein(a). AI and B and parental history in men with early onset of ischaemie heart disease. Lancet 1988; 1: 1070-1073.
35. Rhoads GG. Morto NH. Gulbrandsen CL et al. Sinking pre-beta lipoprotein and coronary heart disease in Japanese-American men in Hawaii. Am J Epidemiol 1978; 108: 350-356.
36. Benz K, Dahlen G. Borresen AL et al. Lp(a) phenolypes. other lipoprotein parameters and family history of heart disease in middle-aged males. Clin Genet 1977; 16: 347-352.
37. Berg K, Dahlen G.FrickMG. Lp( a) lipoprotein on pre-b1-lipoprotein in patients with coronary heart disease. Clin Genet 1974; 6: 230-235.
38. Kostner GM. Avogaro P. Cozzolalo G et al. Lipoprotein Lp(a) and the risk of myocardial infarction. Atherosclerosis 1981; 39: 51-61.
39. Murai A. Miyahara T. Fuji mot o M et til. Lpla) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59: 199-204.
40. Dahlen GH, Guyton JR. Altar MD et al. Association of levels of lipoprotein Lp( a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. Circulation 1986; 74: 758-765.
41. Armstrong VW, Cremer P. Eberle E et al. The association between scrum Lp(a) concentration and angiographieally assessed coronary atherosclerosis: dependence on serum LDL levels. Atherosclerosis 1986; 62: 249-257.
42. Frick MM. Dahlen G. Berg K et a!. Serum lipids in angiographieally assessed coronary atherosclerosis. Chest 1978; 73: 62-65.
43. Morrisett JD. Guyton JR. Gaubatz JW et al. Lipoprotein(a): structure, metabolism and epidemiology. In: Gotto AM Jr, Ed. Plasma Lipoprotein. Amsterdam: Elsevier, 1987.
44. Rosengren A. Wilhelmsen L. Eriksson E et al. Lipoprotein(a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. Br Med J 1990; 301: 1248-1251.
45. Sandkamp M. Funker H, Schulte H et al. Lipoproteinta) is an independent risk factor for myocardial infarction in young age. Clin Chem 1990; 36: 20-23.
46. Kark JD. Sandholzer C, Friedlander Y et al. Plasma Lpta), apolipoprolein(a) isoforms and acute myocardial infarction in men and women: a case control study in the Jerusalem population. Athemsclerosis 1993; 98: 139-151.
47. Brown SA, Morrisset JD, Buerwinkle E et al. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of atherosclerosis risk in comniunities (ARIC) study. Artrrioscler Thromb 1993; 13: 1558-1566.
48. Schreiner PJ, Morrissett JD. Sharrctt AR et al. Lipoproiein(a) as a risk factor for preclinical atherosclerosis. Anerioscier Thromh 1993; 13: 826-833.
49. Wu JH. Kao JT. Wen MS et al. Coronary artery disease risk predicted by plasma concentrations of high-density Itpoprotein cholesterol, apolipoprotein AI, apolipoprotein B and lipoprotein(a) in a general Chinese population. Clin Chem 1993; 39: 209-212.
50. Tenka K, Saikawa T. Maeda T et ni. The relationship betw een serum lipoprotein(a) and restenosis alter initial elective percutaneous transluminal coronary angioplasty. Jpn Cir J 1993; 57: 789-795.
51. Jauhiainen M, Koskinen P. Ehnholm C et al Lipoprotein(a) and coronary heart disease risk: a nested ease-control study of the Helsinki Heart Study participants. Atherosclerosis 1991; 89: 59-67.
52. Haffner SM. Moss SE, Klein BE el al. Lack of association between lipoprotein(a) concentrations and coronary heart disease mortality in diabetes: the Wisconsin epidemiologic sludy of diabetic retinopathy. Metabolism 1992; 41: 194-197.
53. Lyu LC, Shieh MJ, Ordovas JM et ai Plasma lipoprotein and apolipoprotein levels in Taipei and Framingham. Arterioscler Throinh 1993; 13: 1429-1440.
54. Ridker PM, Hennekens CH. Stampfa MJ. A prospective study of lipoprotein(a) and the risk of myocardial infarction. J Ain Med Assoc 1993; 270: 2195-2199.
55. Tervahauta M, Pekkanen J, Kivinen P et ai Prevalence of coronary heart disease and associated risk factors among elderly Finnish men in the Seven Countries study. Atherosclerosis 1993; 104: 47-59.
56. Scanu AM. Fless GM. Lipoprotein(a): heterogeneity and biological relevance. J Clin Invest 1990; 85: 1709-1715.
57. Fless GM, Fisher-Dzoga K. Juhn DJ et ni. Structural and functional changes of rhesus serum low density lipoproteins during cycles of diet-induced hypercholesterolemia. Atherosclerosis 1982; 2: 475-486.
58. Vessby B. Kostner G, Lithell H et ai. Diverging effects of cholestyramine on apolipoprolein B and lipoprotein apo(a). Atherosclerosis 1982; 44: 61-71.
59. Kostner GM, Gavish D, Leopold B et ai HMG CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313-1319.
60. Thiery J, Armstrong VW. Schleef J et al. Scrum lipoprotein Lplat concentrations are not influenced by an HMG CoA reductase inhibitor. Klin Wochechr 1988; 66: 462-463.
61. Mol MJTM. Stuyt PMJ, Demaeker PNM et al. The effects of simvastatin on serum lipoproteins in severe hypercholesierolcmia. Netli J Med 1990; 36: 182-190.
62. Berg K. Leren TP. Unchanged serum lipoproteinuo concentrations with lovastatin. Lancet 1989; 2: 812.
63. Wiklund O. Angelin B. Olofsson SO et al. Apolipoprotcin(a) and ischaemic heart disease in familial hypercholesterolemia. Lancet 1990; 1: 1360-1363.
64. Schmidt HHJ, Wagna S, Manns MP. Elevated lipoprotcin(a) is lowered by a cholesterol synthesis inhibitor in a normocholesterolemic patient with premature myocardial infarction. Blood Consul fibrinolysis 1993;4: 173-175.
65. Dallongeville J. Fruchart JC. Pfister P, Bard JM for the European Fluvasatin Study Group. Effect of fluvastatin on plasma apoB containing particles including Lp(a). J Intern Med 1994; in press.
66. Carlson LA. Hamsten A. Asplund A et al. Pronounced lowering of scrum levels of Hpoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271-276.
67. Gurakar A. Hoeg JM, Kostner G et al. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985; 57: 293-301.
68. Bimmermann A, Boersehmann G. Sehwartzkooff W et al Effective therapeutic measures for reducing lipoprotein(a) in patients with dyslipidemia: lipoprotein(a) reduction with sustained-release bezafibrate. Curr Ther Res 1991; 49: 635-643.
69. Soma M, Eumagalli R, Paoefetti R et al. Plasma Lp(a) concentration after oestrogen and proueslagen in post menopausal women. Lancet 1991; 337: 612.
70. Albers JJ, MacTaggart H. Applebaum-Bowden D et al. Reduction of lecithine cholesterol acyltransferase, apolipoprolein D and Lp(a) lipoprotein with anabolic steroid stanozolol. Biochim Biophys Acta 1984; 795: 293-296.
71. Gavish D, Breslow JL. Lipoprotein(a) reduction by N-aeetyleysteine. Ldtcet 1991; 337: 203-204.
72. Stalenhoef AFH. Kroom AA, Demacker PNM, N-acelylcysteine and lipoprotein(a). Lancet 1991; 337: 49 .